1. A screening procedure is described to assess rapidly the clinical potential of chelating agents for the treatment of Wilson's disease.

2. Rats were used as the test animal; they were kept in metabolic cages and the urine was collected in copper-free containers. The compounds investigated were given by mouth as a standard dose of 100 mg. Copper was determined by atomic absorption spectrophotometry.

3. Basal urine copper excretion was 65·1 ± se 2·93 nmol/24 h (4·1 μg ± 0·185). After penicillamine this rose to 367·1 nmol and after trien to 305·9 nmol.

4. Certain compounds caused a reduction in the amount of copper excreted in the urine, probably by forming insoluble chelates with the metal, hence rendering it unavailable for excretion at the glomerulus.

This content is only available as a PDF.
You do not currently have access to this content.